New Drug Update: 2012
Abstract:Five new drugs that are used for medical problems often experienced by the elderly have been selected for consideration in this review. The uses and most important properties of these agents are considered, and a rating for each new drug is determined. The rating is based on a comparison of the new drug with related drugs already marketed. Advantages, disadvantages, and other important information regarding the new drug are identified and used as the basis for determining the rating.
Keywords: AE = Adverse event; Aclidinium; Bronchodilator; CIC = Chronic idiopathic constipation; COPD = Chronic obstructive pulmonary disease; CSBM = Complete spontaneous bowel movements; Constipation; Elderly; FEV1 = Forced expiratory volume in one second; GC-C = Guanylate cyclase-C; Glaucoma; IBS-C = Irritable bowel syndrome with constipation; IOP = Intraocular pressure; Indacaterol; LABA = Long-acting beta2-adrenergic agonist; Linaclotide; Medications; Mirabegron; NDCR = New Drug Comparison Rating; OAB = Overactive bladder; Overactive bladder; Tafluprost; XL = Extended release; XR = Extended release; cGMP = Cyclic guanosine monophosphate
Document Type: Research Article
Publication date: April 1, 2013
- The Consultant Pharmacist® is the official peer-reviewed journal of the American Society of Consultant Pharmacists. It is dedicated exclusively to the medication needs of the elderly in all settings, including adult day care, ambulatory care, assisted living, community, hospice, and nursing facilities. This award-winning journal is a member benefit of ASCP. Individuals who are not members and wish to receive The Consultant Pharmacist® will want to consider joining ASCP.
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- Ingenta Connect is not responsible for the content or availability of external websites